Blockbuster Drugs Market: Global Industry Analysis and Opportunity Assessment, 2019 – 2025

The global 50 blockbuster drugs market size is estimated to reach a value of US$ 292 billion by 2025.

PUNE , MAHARASHTRA, INDIA, February 28, 2019 /EINPresswire.com/ — Global Blockbuster Drugs Industry

The global 50 blockbuster drugs market size is estimated to reach a value of US$ 292 billion by 2025.

‘’Global Blockbuster Drugs Market 2015 – 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts” presents an in-depth assessment of the global blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook for global blockbuster drugs market. The report includes historic data from 2015 to 2017 and forecasts until 2025.

Try Sample Report @ https://www.wiseguyreports.com/sample-request/3602067-global-blockbuster-drugs-market-2015-2025-top-50

The report contains a granular analysis of the present industry situations, market demands, reveals facts on the market size, revenues and provides forecasts through 2025. The report provides clear insight into current and future developments of the global blockbuster drugs market. The report explores detailed analysis of top 50 drugs market assessment globally from 2015 to 2017 and forecasts to 2025. The report also details the latest information about the global research & development spend by pharma & biotech companies

Additionally, the report includes assessment of most valuable drugs research and development projects insights by phase and market value. Key trends in terms of collaboration, merger & acquisition, partnerships and licensing agreement are analyzed with details. The report also explores detailed description of growth drivers and inhibitors of the global blockbuster drugs market.

The report concludes with the profiles of major players in the global blockbuster drugs market. The key market players are evaluated on various parameters such as business overview and recent development.

The Major Companies Dominating this Market for its Products, Services and Continuous Product Developments are:

1) AbbVie
2) Celgene
3) Gilead Science
4) Merck
5) Roche
6) Bristol–Myers Squibb
7) Pfizer
8) Johnson & Johnson
9) Amgen
10) Biogen
11) Bayer
12) Regeneron Pharmaceuticals
13) Novo Nordisk
14) Allergan
15) Alexion Pharmaceuticals
16) GlaxoSmithKline
17) Novartis
18) Eli Lilly and Company
19) Astrazeneca
20) Incyte Corporation
21) Boehringer Ingelheim
22) Astellas Pharma

Top 50 Blockbuster Drugs Covered Under This Report Are:

1) Humira
2) Imbruvica
3) Revlimid
4) Genvoya
5) Truvada
6) Harvoni
7) Epclusa
8) Keytruda
9) Januvia/Janumet
10) Herceptin
11) Avastin
12) MabThera/Rituxan
13) Perjeta
14) Opdivo
15) Eliquis
16) Orencia
17) Sprycel
18) Lyrica
19) Ibrance
20) Simponi
21) Stelara
22) Zytiga
23) Invega Sustenna
24) Xarelto
25) Enbrel
26) Tagrisso
27) Tecfidera
28) Eylea
29) Victoza
30) Botox
31) Soliris
32) Triumeq
33) Seretide/Advair
34) Gilenya
35) Cosentyx
36) Trulicity
37) Cialis
38) Humalog
39) Symbicort
40) Zepatier
41) Pomalyst/Imnovid
42) Darzalex
43) Prolia/Xgeva
44) Ocrevus
45) Xtandi
46) Tivicay
47) Jakafi/Jakavi
48) Jardiance
49) Trajenta / Jentadueto
50) Relvar/Breo Ellipta

The Latest Industry Data Included in this Report:

Global Top 50 Blockbuster Drugs Market Size & Analysis (2015 – 2025)
Global Top 50 Blockbuster Drugs Market Share & Y–o–Y Growth (%), 2015 – 2025
Global Top 50 Blockbuster Drugs Market Assessment & Opportunity, (2015 – 2025)
Most Valuable Drugs Research and Development (R&D) Projects Insights by Phase and Market Value
Global Research & Development (R&D) Spend by Pharma & Biotech Companies (2015 – 2025)
Major Deals (Mergers, Acquisitions, Key Agreements, Partnerships & Collaborations)
Key Market Drivers and Inhibitors of the Global Blockbuster Drugs Market
Major Companies Analysis

The Answers to the Following Key Questions can be found in the Report:

What is the size of the global top 50 blockbuster drugs market during 2015 -2025?
What will be the revenue generated by each drug during the forecast period?
Which major drugs provides highest market share?
How are the overall market and major drugs growing?
What are the key drivers and inhibitors in the current market?
What will be the impact of drivers and inhibitors in the future?
How is the market predicted to develop in the future?
Who are the key players in this market space?

For Detailed Reading Please visit WiseGuy Reports @ https://www.wiseguyreports.com/reports/3602067-global-blockbuster-drugs-market-2015-2025-top-50

Some Major Points from Table of content:

Executive Summary
Global Top 50 Blockbuster Drugs Market Size& Analysis (2015 – 2025)
Global Top 50 Blockbuster Drugs Market Share & Y–o–Y Growth (%), 2015 – 2025
Key Drivers and Inhibitors of the Global Blockbuster Drugs Market
4.1 Market Drivers
4.2 Market Inhibitors
Global Top 50 Blockbuster Drugs Market Assessment & Opportunity, (2015 – 2025)
5.1 Humira (Adalimumab)
5.2 Imbruvica (Ibrutinib)
5.3 Revlimid (Lenalidomide)
5.4 Pomalyst/Imnovid (Pomalidomide)
5.5 Genvoya (Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide fumarate)
5.6 Truvada (Emtricitabine / Tenofovir)
5.7 Harvoni (Ledipasvir / Sofosbuvir)
5.8 Epclusa (Sofosbuvir / Velpatasvir)
5.9 Keytruda (Pembrolizumab)
5.10 Januvia/Janumet (Sitagliptin / Metformin)
5.11 Herceptin (Trastuzumab)
5.12 Avastin (Bevacizumab)
5.13 MabThera/Rituxan (Rituximab)
5.14 Perjeta (Pertuzumab)
5.15 Opdivo (Nivolumab)
5.16 Eliquis (Apixaban)
5.17 Orencia (Abatacept)
5.18 Sprycel (Dasatinib)
5.19 Lyrica (Pregabalin)
5.20 Ibrance (Palbociclib)
5.21 Simponi (Golimumab)
5.22 Stelara (Ustekinumab)
5.23 Zytiga (Abiraterone acetate)
5.24 Invega Sustenna (Paliperidone)
5.25 Xarelto (Rivaroxaban)
5.26 Tagrisso (Osimertinib)
5.27 Enbrel (Etanercept)
5.28 Eylea (Aflibercept)
5.29 Victoza (Liraglutide)
5.30 Botox (Botulinum toxin)
5.31 Soliris (Eculizumab)
5.32 Triumeq (Abacavir / Dolutegravir / Lamivudine)
5.33 Seretide/Advair (Fluticasone propionate / Salmeterol)
5.34 Gilenya (Fingolimod)
5.35 Cosentyx (Secukinumab)
5.36 Trulicity (Dulaglutide)
5.37 Humalog (Insulin Lispro)
5.38 Cialis (Tadalafil)
5.39 Symbicort (Budesonide / Formoterol)
5.40 Zapatier (Elbasvir / Grazoprevir)
5.41 Tecfidera (Dimethyl fumarate)
5.42 Darzalex (Daratumumab)
5.43 Prolia/Xgeva (Denosumab)
5.44 Ocrevus (Ocrelizumab)
5.45 Xtandi (Enzalutamide)
5.46 Tivicay (Dolutegravir)
5.47 Jakafi/Jakavi (Ruxolitinib Phosphate)
5.48 Jardiance (Empagliflozin)
5.49 Trajenta/Jentadueto (Linagliptin)
5.50 Relvar/Breo Ellipta (Fluticasone furoate / Vilanterol)
Most Valuable Drugs Research and Development (R&D) Projects Insights by Phase and Market Value
Global Research & Development (R&D) Spend by Pharma & Biotech Companies (2015 – 2025)
Major Deals (Mergers, Acquisitions, Key Agreements, Partnerships & Collaborations)

Continued….

For more information or any query mail at sales@wiseguyreports.com

Norah Trent
WISEGUY RESEARCH CONSULTANTS PVT LTD
8411985042
email us here
["facebook", "twitter", "google", "linkedin"]
{"facebook"=>"", "twitter"=>"", "google"=>"", "linkedin"=>""}


Source: EIN Presswire

Global Non-Invasive Prenatal Testing Market: Analysis and Industry Opportunity Assessment, 2019 – 2025

Global NIPT market is anticipated to grow over US$ 2.5 Billion by 2025 with an impressive double-digit growth rate in the forecast period 2018 – 2025.

PUNE , MAHARASHTRA, INDIA, February 28, 2019 /EINPresswire.com/ — Global Non-Invasive Prenatal Testing Industry

New Study on “2018-2025 Non-Invasive Prenatal Testing Market Global Key Player, Demand, Growth, Opportunities and Analysis Forecast” added to Wise Guy Reports Database

Global Non-Invasive Prenatal Testing(NIPT) market is anticipated to grow over US$ 2.5 Billion by 2025 with an impressive double-digit growth rate in the forecast period 2018 – 2025.

The market is driven by number of factors such as high incidence rate of babies born with down syndrome, no risk of miscarriage with NIPT test, shifting trend towards child bearing at advanced maternal age (35 years or older), rising focus on reimbursement for NIPT and increasing preference for non-invasive techniques over invasive methods.

“Global Non-Invasive Prenatal Testing Market: Demand, Insights, Analysis, Opportunities, Growth Potential and Forecast 2018 – 2025” presents an in-depth assessment of the Global Non-Invasive Prenatal Testing (NIPT) market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook for Global Non-Invasive Prenatal Testing (NIPT). The research includes historic data from 2014 to 2017 and forecasts until 2025.

Try Sample Report @ https://www.wiseguyreports.com/sample-request/3206822-global-non-invasive-prenatal-testing-market-demand-insights

The report contains a granular analysis of the present industry situations, market demands, reveal facts on the market size, NIPT test volume, revenues and provides forecasts through 2025. A comprehensive analysis has been done on market share of NIPT tests and Countries-based market. The report also includes assessment of comparative test analysis by companies. Additionally, the report includes insights into the Global perspectives on clinical adoption of NIPT. Key trends in terms of collaboration, partnership, merger & acquisition, venture capital investment, distribution and licensing agreement are analyzed with details. The report also explores detailed description of growth drivers and inhibitors of the Global Non-Invasive Prenatal Testing (NIPT) market.

The report concludes with the profiles of major players in the Global Non-Invasive Prenatal Testing (NIPT) market. The key market players are evaluated on various parameters such as company overview, NIPT test portfolios and latest development and trends of the Non-Invasive Prenatal Testing (NIPT) market.

Key Findings:

United States is anticipated to be the most attractive market in the Global Non-Invasive Prenatal Testing(NIPT) market
• China NIPT test market is set to cross USD 400 Million by 2025
• Panorama test accounted for the highest share in Global Non-Invasive Prenatal Testing(NIPT) market
• Verifi test has the second highest revenue share in the Global Non-Invasive Prenatal Testing(NIPT) market
• Rising focus on Reimbursement for NIPT test will revolutionize the market
• Two–Child policy is likely to boost China NIPT market
The Major Companies Dominating this Market for its Products, Services and Continuous Product Developments are:

Illumina, Natera, Sequenom Laboratories (LabCorp), Ariosa Diagnostics (Roche), BGI Diagnosis Co. Ltd, Berry Genomics, Quest Diagnostics, LifeCodexx AG, Premaitha Health, NIPD Genetics

Major and Promising Non-Invasive Prenatal Testing (NIPT) Covered Under This Report are:

Panorama, MaterniT21 PLUS, Harmony, Verifi, NIFTY, IONA, PrenaTest, Bambni, Veracity and Other Tests

Major Countries Analyzed Under This Report are:

United States, China, Japan, India, Brazil, Australia, New Zealand, United Kingdom, Germany, Italy, Spain, France, Switzerland, Sweden, Belgium, Russia, Turkey, Netherland, Poland, Armenia, Moldova, Denmark and Rest of the Countries.

The Latest Industry Data Included in this Report:

Global Non–Invasive Prenatal Testing Market Volume & Future Trends (2014 – 2025)
• Global Non–Invasive Prenatal Testing Market Revenue & Future Trends (2014 – 2025)
• Global Non–Invasive Prenatal Testing Market Share and Y–o–Y Growth (%)
• Market Share Analysis, by Test, 2014 – 2025 (%)
• Market Share Analysis, by Major Countries, 2014 – 2025 (%)
• Global Non–Invasive Prenatal Testing Market, By Test (Volume and Value),2011 – 2025
• Global Non–Invasive Prenatal Testing Market, By Geography (Volume and Value),2014 – 2025
• Non–Invasive Prenatal Testing(NIPT) Comparative Analysis – By Test
• Major Deals in Global Non–Invasive Prenatal Testing Market
• Global Perspectives on Clinical Adoption of NIPT
• Global Non–Invasive Prenatal Testing Market Drivers and Inhibitors
• Key Companies Analysis
Some points from table of content:

REPORT SUMMARY
1. Executive Summary
2. Market Size & Analysis: Global Non–Invasive Prenatal Testing (Volume & Value),2014 – 2025
2.1.1 Global Non–Invasive Prenatal Testing Market Volume & Forecast
2.1.2 Global Non–Invasive Prenatal Testing Market Revenue & Forecast
3. Global Non–Invasive Prenatal Testing Market Share and Y–o–Y Growth (%)
3.1 Market Share Analysis, by Test, 2014 – 2025 (%)
3.1.1 Global Non-Invasive Prenatal Testing Market Volume Share, by Test, 2014 – 2025
3.1.2 Global Non-Invasive Prenatal Testing Market Revenue Share, by Test, 2014 – 2025
3.2 Market Share Analysis, by Major Countries, 2014 – 2025 (%)
3.2.1 Global Non-Invasive Prenatal Testing Market Volume Share, by Major Countries, 2014 – 2025
3.2.2 Global Non-Invasive Prenatal Testing Market Revenue Share, by Major Countries, 2014 – 2025
4. Non–Invasive Prenatal Testing(NIPT) Comparative Analysis – By Test
5. Global Non–Invasive Prenatal Testing Market Drivers and Inhibitors
5.1 Market Drivers
5.2 Market Inhibitors

For Detailed Reading Please visit WiseGuy Reports @ https://www.wiseguyreports.com/reports/3206822-global-non-invasive-prenatal-testing-market-demand-insights

6. Global Non–Invasive Prenatal Testing Market, By Test (Volume and Value),2011 – 2025
6.1 Panorama Test
6.1.1 Panorama Test Volume (Number of Tests Performed) & Forecast
6.1.2 Panorama Test Market Revenue & Forecast
6.2 MaterniT21 Plus Test
6.2.1 MaterniT21 Plus Test Volume (Number of Tests Performed) & Forecast
6.2.2 MaterniT21 Plus Test Market Revenue & Forecast
6.3 Harmony Test
6.3.1 Harmony Test Volume (Number of Tests Performed) & Forecast
6.3.2 Harmony Test Market Revenue & Forecast
6.4 NIFTY Test
6.4.1 NIFTY Test Volume (Number of Tests Performed) & Forecast
6.4.2 NIFTY Test Market Revenue & Forecast
6.5 Verifi Test
6.5.1 Verifi Test Volume (Number of Tests Performed) & Forecast
6.5.2 Verifi Prenatal Test Market Revenue & Forecast
6.6 IONA Test
6.6.1 IONA Test Volume (Number of Tests Performed) & Forecast
6.6.2 IONA Test Market Revenue & Forecast
6.7 Prena Test
6.7.1 Prena Test Volume (Number of Tests Performed) & Forecast
6.7.2 Prena Test Market Revenue & Forecast
6.8 Bambni Test
6.8.1 Bambni Test Volume (Number of Tests Performed) & Forecast
6.8.2 Bambni Test Market Revenue & Forecast

Norah Trent
WISEGUY RESEARCH CONSULTANTS PVT LTD
841-198-5042
email us here
["facebook", "twitter", "google", "linkedin"]
{"facebook"=>"", "twitter"=>"", "google"=>"", "linkedin"=>""}


Source: EIN Presswire

Outbound MICE Tourism Market: China Industry Analysis and Opportunity Assessment, 2019 – 2025

China Outbound Meetings, Incentives, Conferences and Exhibitions (MICE) tourism market is expected to surpass US$ 28 Billion by 2025.

PUNE , MAHARASHTRA, INDIA, February 28, 2019 /EINPresswire.com/ — China Outbound MICE Tourism Industry

China Outbound Meetings, Incentives, Conferences and Exhibitions (MICE) tourism market is expected to surpass US$ 28 Billion by 2025.

“China Outbound MICE Tourism Market Report, Analysis and Forecast to 2025” offers the most up–to–date industry data on the actual market situation and future outlook for China outbound MICE tourism market. The report uses data and analysis to discuss potential lucrative opportunities and future trends related to China outbound MICE travelers flow, revenue and main destination markets. The report provides clear insight into current and future tourism developments of the China outbound MICE tourism market. Furthermore, this report uses country focused analysis to explore China outbound MICE tourism market.

A detailed country-wise analysis of the market is provided, covering a total of 21 countries. The research study limelight growth drivers and investigates market inhibitors of China outbound MICE tourism market.

The countries included in this report are Hong Kong, Thailand, South Korea, Macau, India Singapore, Malaysia, Japan, United States, Philippines, Vietnam, Cambodia, Indonesia, Germany, France, Italy, Switzerland, Russia, United Kingdom, Spain, Australia and Other Countries

Try Sample Report @ https://www.wiseguyreports.com/sample-request/3349656-china-outbound-mice-tourism-market-report-analysis-and-forecast-to-2025

Further key findings from the report suggest:

China is one of the fastest growing outbound MICE tourism markets
• Chinese MICE travelers made nearly 5 million trips in 2017.
• United States and Hong Kong generates the highest revenue in the market
• Japan is anticipated to register fastest growth rate over the forecast period
The Latest Industry Data Included in this Report:

Market Size & Analysis: China Outbound Travelers Visitation & Spending (2013 – 2025)
• China Outbound Travelers Visitation & Forecast (2013 – 2025)
• China Outbound Travelers Spending & Forecast (2013 – 2025)
• Market Size & Analysis: China Outbound MICE Travelers Visitation & Spending (2013 – 2025)
• China Outbound MICE Travelers Visitation & Forecast (2013 – 2025)
• China Outbound MICE Travelers Spending & Forecast (2013 – 2025)
• China Outbound MICE Travelers Visitation & Spending Share & Y-o-Y Growth (%) (2013 – 2025)
• China MICE Travelers Visitation to Major 21 Countries & Forecast (2013 – 2025)
• China MICE Travelers Spending to Major 21 Countries & Forecast (2013 – 2025)
• Identification of Key Market Drivers and Inhibitors of the China Outbound MICE Tourism Market
For Detailed Reading Please visit WiseGuy Reports @ https://www.wiseguyreports.com/reports/3349656-china-outbound-mice-tourism-market-report-analysis-and-forecast-to-2025

Some Major Points from Table of content:

Executive Summary
Market Size & Analysis: China Outbound Travelers Visitation & Spending (2013 – 2025)
2.1 China Outbound Travelers Visitation & Forecast
2.2 China Outbound Travelers Spending & Forecast
Market Size & Analysis: China Outbound MICE Travelers Visitation & Spending (2013 – 2025)
3.1 China Outbound MICE Travelers Visitation & Forecast
3.2 China Outbound MICE Travelers Spending & Forecast
China Outbound MICE Travelers Visitation & Spending Share & Y-o-Y Growth (%) (2013 – 2025)
4.1 China Outbound MICE Travelers Visitation Share & Forecast
4.2 China Outbound MICE Travelers Spending Share & Forecast
Key Market Drivers and Inhibitors of the China Outbound MICE Travelers Market
5.1 Market Drivers
5.2 Market Inhibitors
China Outbound MICE Travelers Visitation & Spending – Top 21 Countries In-depth Analysis (2013 – 2025)
6.1 Thailand – China Outbound MICE Travelers Visitation & Spending
6.1.1 China Outbound MICE Travelers Visitation to Thailand & Forecast
6.1.2 China Outbound MICE Travelers Spending in Thailand & Forecast
6.2 Hong Kong – China Outbound MICE Travelers Visitation & Spending
6.2.1 China Outbound MICE Travelers Visitation to Hong Kong & Forecast
6.2.2 China Outbound MICE Travelers Spending in Hong Kong & Forecast
6.3 South Korea – China Outbound MICE Travelers Visitation & Spending
6.3.1 China Outbound MICE Travelers Visitation to South Korea & Forecast
6.3.2 China Outbound MICE Travelers Spending in South Korea & Forecast
6.4 Macau – China Outbound MICE Travelers Visitation & Spending
6.4.1 China Outbound MICE Travelers Visitation to Macau & Forecast
6.4.2 China Outbound MICE Travelers Spending in Macau & Forecast
6.5 India – China Outbound MICE Travelers Visitation & Spending
6.5.1 China Outbound MICE Travelers Visitation to India & Forecast
6.5.2 China Outbound MICE Travelers Spending in India & Forecast
6.6 Singapore – China Outbound MICE Travelers Visitation & Spending
6.6.1 China Outbound MICE Travelers Visitation to Singapore & Forecast
6.6.2 China Outbound MICE Travelers Spending in Singapore & Forecast
6.7 Malaysia – China Outbound MICE Travelers Visitation & Spending
6.7.1 China Outbound MICE Travelers Visitation to Malaysia & Forecast
6.7.2 China Outbound MICE Travelers Spending in Malaysia & Forecast
6.8 Japan – China Outbound MICE Travelers Visitation & Spending
6.8.1 China Outbound MICE Travelers Visitation to Japan & Forecast
6.8.2 China Outbound MICE Travelers Spending in Japan & Forecast
6.9 United States – China Outbound MICE Travelers Visitation & Spending
6.9.1 China Outbound MICE Travelers Visitation to United States & Forecast
6.9.2 China Outbound MICE Travelers Spending in United States & Forecast
6.10 Philippines – China Outbound MICE Travelers Visitation & Spending
6.10.1 China Outbound MICE Travelers Visitation to Philippines & Forecast
6.10.2 China Outbound MICE Travelers Spending in Philippines & Forecast
6.11 Vietnam – China Outbound MICE Travelers Visitation & Spending
6.11.1 China Outbound MICE Travelers Visitation to Vietnam & Forecast
6.11.2 China Outbound MICE Travelers Spending in Vietnam & Forecast
6.12 Cambodia – China Outbound MICE Travelers Visitation & Spending
6.12.1 China Outbound MICE Travelers Visitation to Cambodia & Forecast
6.12.2 China Outbound MICE Travelers Spending in Cambodia & Forecast
6.13 Indonesia – China Outbound MICE Travelers Visitation & Spending
6.13.1 China Outbound MICE Travelers Visitation to Indonesia & Forecast
6.13.2 China Outbound MICE Travelers Spending in Indonesia & Forecast
6.14 Germany – China Outbound MICE Travelers Visitation & Spending
6.14.1 China Outbound MICE Travelers Visitation to Germany & Forecast
6.14.2 China Outbound MICE Travelers Spending in Germany & Forecast
6.15 France – China Outbound MICE Travelers Visitation & Spending
6.15.1 China Outbound MICE Travelers Visitation to France & Forecast
6.15.2 China Outbound MICE Travelers Spending in France & Forecast
6.16 Italy – China Outbound MICE Travelers Visitation & Spending

Norah Trent
WISEGUY RESEARCH CONSULTANTS PVT LTD
8411985042
email us here
["facebook", "twitter", "google", "linkedin"]
{"facebook"=>"", "twitter"=>"", "google"=>"", "linkedin"=>""}


Source: EIN Presswire

Diabetes Insulin Delivery Pens Market: Global Industry Analysis and Opportunity Assessment, 2019 – 2025

Diabetes Insulin Delivery Pen market will surpass US$ 14.4 Billion by 2025

PUNE , MAHARASHTRA, INDIA, February 28, 2019 /EINPresswire.com/ — Global Diabetes Insulin Delivery Pens Industry

New Study On “2018-2025 Diabetes Insulin Delivery Pens Market Global Key Player, Demand, Growth, Opportunities and Analysis Forecast” Added to Wise Guy Reports Database

Diabetes Insulin Delivery Pen market will surpass US$ 14.4 Billion by 2025.

Market growth can be attributed to factors such as growing diabetes patient population, high adoption rate, user–friendly design, rising popularity among consumers, help avoid over/under–dosing of insulin, rising market demand for human insulin analogs, government support and technological advancements in the field of insulin pen devices

“Diabetes Insulin Delivery Pens Market Research Report 2018”presents an in-depth assessment of the diabetes insulin delivery pen market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook for diabetes insulin delivery pen market. The report includes historic data from 2011 to 2017 and forecasts until 2025.

Try Sample Report @ https://www.wiseguyreports.com/sample-request/3408696-diabetes-insulin-delivery-pens-market-research-report-2018

The report contains a granular analysis of the present industry situations, market demands, reveal facts on the market size, insulin pen volume, revenues for insulin pen and its segments reusable and disposable insulin pen and illustrative forecast to 2025.It also provides an all-round analysis of overall number of patients with diabetes and insulin users. A comprehensive analysis has been done on market share of diabetes insulin delivery pen segment and countries-based market.The report also explores detailed description of growth drivers and inhibitors of the diabetes insulin delivery pens market.

The superior geographic segments are identified in the report, which also studies the prospects showcased by the emerging markets. It covers United States, United Kingdom, France, Italy, Spain, Germany, Japan, China, India and Brazil from 2011 to 2017 and forecasts to 2025.

The report concludes with the profiles of major players in the diabetes insulin delivery pens market. The key market players are evaluated on various parameters such as company overview, product portfolios and recent development of the diabetes insulin delivery pens market.

Market segment by Type, the product can be split into

Reusable Insulin Pens
• Disposable Insulin Pens
The Major Companies Dominating this Market for its Products, Services and Continuous Product Developments are:

Novo Nordisk, Eli Lilly, Sanofi, Owen Mumford, Ypsomed, Biocon Ltd.

Major Countries Analyzed Under This Report are:

United States, United Kingdom, France, Italy, Spain, Germany, Japan, China, India and Brazil

The Latest Industry Data Included in this Report:

Diabetes Population in 10 major markets(10MM) 2011-2025
• Insulin Users Insights in 10 major markets(10MM) 2011 – 2025
• Total Diabetes Insulin Delivery Pen Users (Volume),2011 – 2025
• Reusable (Cartridge) Insulin Delivery Pen Users (Volume),2011 – 2025
• Prefilled (Disposable) Insulin Delivery Pen Users (Volume),2011 – 2025
• Total Diabetes Insulin Delivery Pen Market Size & Analysis (Value)2011-2025
• Reusable (Cartridge) Insulin Delivery Pen Market (Value),2011-2025
• Prefilled (Disposable) Insulin Delivery Pen Market (Value),2011-2025
• Total Diabetes Insulin Delivery Pen Market Share, By Users (%),2011 – 2025
• Reusable (Cartridge) Insulin Delivery Pen Market Share, By Users (%)2011 – 2025
• Prefilled (Disposable) Insulin Delivery Pen Market Share, By Users (%), 2011 – 2025
• Total Diabetes Insulin Delivery Pen Market Share (%),2011 – 2025
• Reusable (Cartridge) Insulin Delivery Pen Market Share (%),2011 – 2025
• Prefilled (Disposable) Insulin Delivery Pen Market Share (%),2011 – 2025
• Diabetes Insulin Delivery Pen Market, By Geography (Volume and Value),2011 – 2025
• Market Definition for the Specified Topic Along with Identification of Key Drivers
and Inhibitors for the Market
• A Comprehensive List of Key Market Players Along with the Analysis of their Current
Product Portfolios and Recent Development
For Detailed Reading Please visit WiseGuy Reports @ https://www.wiseguyreports.com/reports/3408696-diabetes-insulin-delivery-pens-market-research-report-2018

Some Major Points from Table of content:

Executive Summary
Diabetes Insulin Delivery Pen Users (Volume),2011 – 2025
2.1 Diabetes Reusable (Cartridge) Insulin Delivery Pen Users (Volume),2011 – 2025
2.2 Diabetes Prefilled (Disposable) Insulin Delivery Pen Users (Volume),2011 – 2025

Diabetes Insulin Delivery Pen Market Size & Analysis (Value)2011-2025
3.1 Diabetes Reusable (Cartridge) Insulin Delivery Pen Market (Value),2011-2025
3.2 Diabetes Prefilled (Disposable) Insulin Delivery Pen Market (Value),2011-2025
Diabetes Insulin Delivery Pen Market Share, By Users (%),2011 – 2025
4.1 Diabetes Reusable (Cartridge) Insulin Delivery Pen Market Share, By Users (%)2011 – 2025
4.2 Diabetes Prefilled (Disposable) Insulin Delivery Pen Market Share, By Users (%), 2011 – 2025
Diabetes Insulin Delivery Pen Market Share (%),2011 – 2025
5.1 DiabtesReusable (Cartridge) Insulin Delivery Pen Market Share (%),2011 – 2025
5.2 Diabetes Prefilled (Disposable) Insulin Delivery Pen Market Share (%),2011 – 2025
Key Market Drivers & Inhibitors of the Diabetes Insulin Delivery Pen Market
6.1 Market Drivers
6.2 Market Inhibitors
Diabetes Insulin Delivery Pen Market & Forecast (2011 – 2025) – Geographical Landscape
7.1 United States
7.1.1 Overall Diabetes Population & Forecast (Volume)
7.1.2 Insulin Users & Forecast (Volume)
7.1.3 Overall Diabetes Insulin Delivery Pen Users & Forecast (Volume)
7.1.3.1 Diabetes Reusable (Cartridge) Insulin Delivery Pen Users(Volume)
7.1.3.2 Diabetes Prefilled (Disposable) Insulin Delivery Pen Users (Volume)
7.1.4 Overall Diabetes Insulin Delivery Pen Market & Forecast (Value)
7.1.4.1 Diabetes Reusable (Cartridge) Insulin Delivery Pen Market & Forecast(Value)
7.1.4.2 Diabetes Prefilled (Disposable) Insulin Delivery Pen Market & Forecast (Value)
7.2 Germany
7.2.1 Overall Diabetes Population & Forecast (Volume)
7.2.2 Insulin Users & Forecast (Volume)
7.2.3 Overall Diabetes Insulin Delivery Pen Users & Forecast (Volume)
7.2.3.1 Diabetes Reusable (Cartridge) Insulin Delivery Pen Users & Forecast (Volume)
7.2.3.2 Diabetes Prefilled (Disposable) Insulin Delivery Pen Users & Forecast (Volume)
7.2.4 Overall Diabetes Insulin Delivery Pen Market & Forecast (Value)
7.2.4.1 Diabetes Reusable (Cartridge) Insulin Delivery Pen Market & Forecast (Value)
7.2.4.2 Diabetes Prefilled (Disposable) Insulin Delivery Pen Market & Forecast (Value)
7.3 France
7.3.1 Overall Diabetes Population & Forecast (Volume)
7.3.2 Insulin Users & Forecast (Volume)
7.3.3 Overall Diabetes Insulin Delivery Pen Users & Forecast (Volume)
7.3.3.1 Diabetes Reusable (Cartridge) Insulin Delivery Pen Users & Forecast (Volume)
7.3.3.2 Diabetes Prefilled (Disposable) Insulin Delivery Pen Users & Forecast (Volume)
7.3.4 Overall Diabetes Insulin Delivery Pen Market & Forecast (Value)
7.3.4.1 Diabetes Reusable (Cartridge) Insulin Delivery Pen Market & Forecast (Value)

Norah Trent
WISEGUY RESEARCH CONSULTANTS PVT LTD
841-198-5042
email us here
["facebook", "twitter", "google", "linkedin"]
{"facebook"=>"", "twitter"=>"", "google"=>"", "linkedin"=>""}


Source: EIN Presswire

Influenza Vaccines Market: United States Industry Analysis and Opportunity Assessment, 2019 – 2025

United States Influenza Vaccines market is set to touch US$ 3.5 Billion threshold by 2025.

PUNE , MAHARASHTRA, INDIA, February 28, 2019 /EINPresswire.com/ — United States Influenza Vaccines Industry

United States Influenza Vaccines market is set to touch US$ 3.5 Billion threshold by 2025.

“United States Influenza Vaccines Market Report, Analysis and Forecast to 2025” presents an in-depth assessment of the United States influenza vaccines market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook for United States influenza vaccines market. The report includes historic data from 2013 to 2017 and forecasts until 2025.

Try Sample Report @ https://www.wiseguyreports.com/sample-request/3471293-united-states-influenza-vaccines-market-report-analysis-and-forecast-to-2025

The report contains a granular analysis of the present industry situations, market demands, reveal facts on the market size, revenues and provides forecasts through 2025.The report provides clear insight into current and future developments of the united states influenza vaccines market. The report also explores detailed analysis of number of children and adults vaccinated with influenza vaccines in United States from 2013 to 2017 and forecasts to 2025. The report also details the latest information about the influenza vaccines production, supply, and allocation by major companies in United States.

A comprehensive analysis has been done on pricing, distribution & demand and effectiveness of influenza vaccines in United States. It also provides a deep and thorough evaluation of distribution channel & technique of influenza vaccination. It covers reimbursement pattern and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, promising influenza vaccines in the clinical development and rapid diagnostic testing for the management of influenza. Key trends in terms of collaboration, merger & acquisition, distribution, exclusive and licensing agreement are analyzed with details. The report also explores detailed description of growth drivers and inhibitors of the United States influenza vaccines market.

The report concludes with the profiles of major players in the United States influenza vaccines market. The key market players are evaluated on various parameters such as company overview, influenza vaccines portfolios, sales value analysis and recent development of influenza vaccine market. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi TanabePharma and Biondvax Pharmaceuticals Ltd, are making novel technology-based influenza vaccines which is likely to affect the market share during the forecast period.

The major companies dominating this market for its products, services and continuous product developments are:

Seqirus, Sanofi Pasteur, GlaxoSmithKline (GSK) and AstraZeneca

The Latest Industry Data Included in this Report:

United States Influenza Vaccines Market Size & Analysis (2013 – 2025)
• United States Number of Persons Vaccinated with Influenza Vaccines (2013 – 2025)
• United States Number of Children Vaccinated with Influenza Vaccines (2013 – 2025)
• United States Number of Adults Vaccinated with Influenza Vaccines (2013 – 2025)
• United States Influenza Vaccines Pricing Trends & Analysis
• United States Influenza Vaccines Production, Supply, and Allocation (By Companies)
• United States Influenza Vaccines Distribution & Demand (2010 – 2018)
• Effectiveness of Influenza Vaccines in United States (2004 – 2018)
• Rapid Diagnostic Testing for the Management of Influenza
• Distribution Channel & Technique of Influenza Vaccination in United States
• United States Influenza Vaccines Reimbursement Policies & Regulatory System
• Major Deals in United States Influenza Vaccines Market
• Promising Influenza Vaccines in Clinical Development
• Influenza Vaccines Clinical Trial Insights by Phase, Company & Country
• Market Definition for the Specified Topic Along with Identification of Key Driver and Inhibitors for the Market
• A Comprehensive List of Key Market Players Along with the Analysis of their Current
Vaccines Portfolios, Sales Value Analysis and Recent Development
Key questions answered in this research report:

At what pace is the influenza vaccines market growing in United States? What will be growth trend in future?
• How much number of persons being vaccinated with influenza vaccines during 2013 – 2025?
• What are the key drivers and inhibitors in the current market? What will be the impact of drivers and inhibitors in the future?
• What are the various influenza vaccines available in the United States?
• How is the market predicted to develop in the future?
• Who are the key players in this market space?
For Detailed Reading Please visit WiseGuy Reports @ https://www.wiseguyreports.com/reports/3471293-united-states-influenza-vaccines-market-report-analysis-and-forecast-to-2025

Some Major Points from Table of content:

Executive Summary
United States Influenza Vaccines Market Size & Analysis (2013 – 2025)
United States Number of Persons Vaccinated with Influenza Vaccines (2013 – 2025)
3.1 Number of Children Vaccinated with Influenza Vaccines
3.2 Number of Adults Vaccinated with Influenza Vaccines
Key Drivers and Inhibitors of the United States Influenza Vaccines Market
4.1 Market Drivers
4.2 Market Inhibitors
United States Influenza Vaccines Pricing Trends & Analysis
United States Influenza Vaccines Production, Supply, and Allocation (By Companies)
United States Influenza Vaccines Distribution & Demand (2010 – 2018)
Effectiveness of Influenza Vaccines in United States (2004 – 2018)
Rapid Diagnostic Testing for the Management of Influenza
Distribution Channel & Technique of Influenza Vaccination in United States
United States Influenza Vaccines Reimbursement Policies & Regulatory System
11.1 Reimbursement Policies
11.2 Regulation System
Major Deals in United States Influenza Vaccines Market
12.1 Merger & Acquisitions
12.2 Collaboration Deal
12.3 Licensing Agreement
12.4 Exclusive Agreement
12.5 Distribution Agreement
Continued…..

For more information or any query mail at sales@wiseguyreports.com

About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:
Norah Trent
+1 646 845 9349 / +44 208 133 9349
Follow on LinkedIn: https://www.linkedin.com/company/wise-guy-research-consultants-pvt-ltd-?trk=biz-companies-cym

Norah Trent
WISEGUY RESEARCH CONSULTANTS PVT LTD
841-198-5042
email us here
["facebook", "twitter", "google", "linkedin"]
{"facebook"=>"", "twitter"=>"", "google"=>"", "linkedin"=>""}


Source: EIN Presswire

Vaccines Market: United States Industry Analysis and Opportunity Assessment, 2019 – 2025

United States vaccines market is set to surpass US$ 21 Billion threshold by 2025.

PUNE , MAHARASHTRA, INDIA, February 28, 2019 /EINPresswire.com/ — United States Vaccines Industry

United States vaccines market is set to surpass US$ 21 Billion threshold by 2025.

“United States Vaccines Market 2015 – 2025: Top 21 Vaccines Analysis, Deal Trends, Players and Forecasts” presents an in-depth assessment of the United States vaccines market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook for United States vaccines market. The report includes historic data from 2015 to 2017 and forecasts until 2025.

Try Sample Report @ https://www.wiseguyreports.com/sample-request/3548036-united-states-vaccines-market-2015-2025-top-21

The report contains a granular analysis of the present industry situations, market demands, reveal facts on the market size, revenues and provides forecasts through 2025.The report provides clear insight into current and future developments of the United States vaccines market. The report also explores detailed analysis of top 21 vaccines market assessment in United States from 2015 to 2017 and forecasts to 2025. The report also details the latest information about the vaccines pricing trends and regulatory landscape in United States.

Additionally, the report includes assessment of promising vaccines in the clinical development by major companies. Key trends in terms of collaboration, merger & acquisition, distribution, exclusive and licensing agreement are analyzed with details. The report also explores detailed description of growth drivers and inhibitors of the United States vaccines market.

The report concludes with the profiles of major players in the United States vaccines market. The key market players are evaluated on various parameters such as business overview, promising vaccines in the clinical development and recent development.

The major companies dominating this market for its products, services and continuous product developments are:

Pfizer, Merck, Sanofi Pasteur and GlaxoSmithKline(GSK)

Top 21 Vaccines Covered Under This Report Are:

Prevnar/Prevnar 13
• Gardasil/Gardasil 9
• Fluzone
• Varivax
• Menactra
• Proquad
• Pneumovax
• FluLaval/Fluarix
• Havrix/Twinrix/Engerix-B
• MMR II
• Adacel
• Boostrix
• Bexsero
• Menveo
• Trumenba
• Shingrix
• Pentacel
• Recombivax HB
• Rotateq
• Rotarix
• Pediarix/Infanrix
The Latest Industry Data Included in this Report:

• United States Vaccines Market Size & Analysis (2015 – 2025)
• United States Vaccines Market Share & Y-o-Y Growth (%), 2015 – 2025
• United States Top 21 Vaccines Market Assessment & Opportunity (2015 – 2025)
• United States Vaccines Pricing Trends & Analysis
• United States Vaccines Regulatory System
• Major Deals in United States Vaccines Market
• Promising Vaccines in Clinical Development by Major Companies
• Key Market Drivers and Inhibitors of the United States Vaccines Market
• Major Companies Analysis

The answers to the following key questions can be found in the report:

What is the size of the United States vaccines market during 2015 -2025?
• What will be the revenue generated by each vaccine during the forecast period?
• Which major vaccine provides highest market share?
• How are the overall market and vaccine type growing?
• What are the key drivers and inhibitors in the current market? What will be the
impact of drivers and inhibitors in the future?
• What are the various vaccines available in the United States?
• How is the market predicted to develop in the future?
• Who are the key players in this market space?
For Detailed Reading Please visit WiseGuy Reports @ https://www.wiseguyreports.com/reports/3548036-united-states-vaccines-market-2015-2025-top-21

Some Major Points from Table of content:

ExecutiveSummary
United States Vaccines Market Size & Analysis (2015 – 2025)
United States Vaccines Market Share & Y-o-Y Growth (%), 2015 – 2025
Key Drivers and Inhibitors of the United States Vaccines Market
4.1 Market Drivers
4.2 Market Inhibitors
United States Top 21 Vaccines Market Assessment & Opportunity (Value),2015 – 2025
5.1 Prevnar/Prevnar 13
5.2 Gardasil/Gardasil 9
5.3 Fluzone
5.4 Varivax
5.5 Menactra
5.6 Proquad
5.7 Pneumovax 23
5.8 Fluarix/FluLaval
5.9 Havrix/Twinrix/Engerix-B
5.10 M-M-R II
5.11 Adacel
5.12 Boostrix
5.13 Bexsero
5.14 Menveo
5.15 Trumenba
5.16 Shingrix
5.17 Pentacel
5.18 Recombivax HB
5.19 Rotateq
5.20 Rotarix
5.21 Pediarix/Infanrix
5.22 Other Vaccines
Continued….

For more information or any query mail at sales@wiseguyreports.com

About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:
Norah Trent
+1 646 845 9349 / +44 208 133 9349
Follow on LinkedIn: https://www.linkedin.com/company/wise-guy-research-consultants-pvt-ltd-?trk=biz-companies-cym

Norah Trent
WISEGUY RESEARCH CONSULTANTS PVT LTD
8411985042
email us here
["facebook", "twitter", "google", "linkedin"]
{"facebook"=>"", "twitter"=>"", "google"=>"", "linkedin"=>""}


Source: EIN Presswire

Asia-Pacific Integrated Operating Room Systems 2019 Market Expected to Grow at CAGR of 12.20% and Forecast to 2025

Wiseguyreports.Com Publish New Market Report On -“Asia-Pacific Integrated Operating Room Systems Market – Analysis, Size, Share, Trends, Growth 2019 – 2025”

PUNE, INDIA, February 28, 2019 /EINPresswire.com/ —

Asia-Pacific Integrated Operating Room Systems Market 2019

An operating room integration system simplifies various operating room protocols by consolidating data and controls in a central command station. This enables the surgical staff to perform a majority of their tasks efficiently, without the need to move around the operating room.
Factors such as increasing number of surgeries, favorable reimbursement policies, and benefits of minimum congestion and streamlined flow of information are expected to drive market growth during the forecast period. However, the high cost of surgeries and hospitalization, followed by associated risks, hamper market growth.

The Asia-Pacific integrated operating room systems market has been segmented on the basis of device, surgical application, type, and region. On the basis of device, the market has been divided into operating table types, operating room lights, intraoperative diagnostic devices, and operating room communication systems.

On the basis of surgical application, the Asia-Pacific integrated operating room systems market has been segmented into therapeutics application and diagnostics imaging application.

On the basis of type, the Asia-Pacific integrated operating room systems market has been segmented into operating room and procedure scheduling system, recording and documentation system, instrument tracking system, audio and video management system, operating room inventory management system, and anesthesia information management.

The Asia-Pacific integrated operating room systems market accounted for USD 145.4 million in 2015 and is expected to register a CAGR of 12.20% during the forecast period.

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/3770602-asia-pacific-integrated-operating-room-systems-market-research

Key Players
Some of the key players in the Asia-Pacific integrated operating room systems market are Stryker Corporation, Skytron, LLC, Danaher Corporation (Leica Microsystems GmbH), Olympus Corporation of the Americas (Image Stream Medical, Inc.), Barco, Johnson & Johnson Services Inc., GE Healthcare, Cook Medical, Karl Storz GmbH & Co. KG, Koninklijke Philips N.V., and Canon Inc., Steris PLC, and Others.

Study Objectives
• To provide a detailed analysis of the market structure along with the forecast of various segments and sub-segments of the Asia-Pacific integrated operating room systems market
• To provide insights into factors influencing and affecting market growth
• To provide historical, current, and forecast revenue of market segments based on device, surgical application, and type
• To provide historical, current, and forecast revenue of market segments and sub-segments with respect to regional markets and key countries
• To provide strategic profiling of key players in the market, comprehensively analyzing their market shares, core competencies, and drawing a competitive landscape for the market
• To provide economic factors, technology trends, and market trends that influence the Asia-Pacific integrated operating room systems market

Target Audience
• Hospitals and clinics
• Research institutes
• Pharmaceutical & biotechnology industries
• Suppliers and distributors
• Potential investors
• Raw material suppliers
• Government associations

Key Findings
• The Asia-Pacific integrated operating room systems market is expected to reach a value of USD 367.2 million by 2023 at a CAGR of 12.20%.
• On the basis of device, the intraoperative diagnostic devices segment is projected to be the largest, registering a CAGR of 12.66% during the forecast period.
• On the basis of surgical application, the therapeutics segment is expected to account for the larger market share of 12.53% from 2018 to 2023.
• By type, the anesthesia information management segment is expected to be the largest at USD 84.8 million by 2023.
• On the basis of region, the market has been segmented into India, Australia, Malaysia, Singapore, Taiwan, Thailand, Hong Kong, Indonesia, and the Rest of Asia-Pacific. The market in the Rest of Asia-Pacific is expected to be the largest at an estimated value of USD 63.1 million by 2023.
• India is projected to be the fastest-growing market at a CAGR of 12.65% from 2018 to 2023.

The report also offers regional analysis.
• Asia-Pacific
o India
o Australia
o Malaysia
o Singapore
o Taiwan
o Thailand
o Hong Kong
o Indonesia
o Rest of Asia-Pacific

Complete Report Details @ https://www.wiseguyreports.com/reports/3770602-asia-pacific-integrated-operating-room-systems-market-research

Table of Contents –Analysis of Key Points
1 Report Prologue
2 Market Introduction
2.1 Introduction
2.2 Assumptions & Limitations
2.3 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing Number of Surgeries
4.2.2 Favorable Reimbursement Policies
4.2.3 Benefits of Minimum Congestion and Streamlined Flow of Information
4.2.4 Drivers Impact Analysis
4.3 Restraints
4.3.1 High Costs of Surgeries and Hospitalization
4.3.2 Risks Factors Associated with Surgeries
4.3.3 Restraints Impact Analysis
4.4 Opportunity
4.4.1 The Rise of Medical Tourism in India
……
11 Company Profiles
11.1 Stryker Corporation.
11.1.1 Financial Overview
11.1.2 Products Offering
11.1.3 Key Developments
11.1.4 SWOT Analysis
11.1.5 Key Strategy
11.2 Skytron, LLC
11.2.1 Company Overview
11.2.2 Financial Overview
11.2.3 Products Offering
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.2.6 Key Strategy
11.3 Danaher Corporation (Leica Microsystems GmbH)
11.3.1 Company Overview
11.3.2 Financial Overview
11.3.3 Products Offering
11.3.4 Key Developments
11.3.5 SWOT Analysis
11.3.6 Key Strategy
11.4 Olympus Corporation of the Americas (Image Stream Medical, Inc.)
11.4.1 Company Overview
11.4.2 Financial Overview
11.4.3 Products Offering
11.4.4 Key Developments
11.4.5 SWOT Analysis
11.4.6 Key Strategy
11.5 Barco.
11.5.1 Company Overview
11.5.2 Financial Overview
11.5.3 Products Offering
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.5.6 Key Strategy
11.6 Johnson & Johnson Services Inc.
11.6.1 Company Overview
11.6.2 Financial Overview
11.6.3 Products Offering
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.6.6 Key Strategy
11.7 GE Healthcare
11.7.1 Company Overview
11.7.2 Financial Overview
11.7.3 Products Offering
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.7.6 Key Strategy
Continued…..

Norah Trent
wiseguyreports
646 845 9349 / +44 208 133 9349
email us here
["facebook", "twitter", "google", "linkedin"]
{"facebook"=>"", "twitter"=>"", "google"=>"", "linkedin"=>""}


Source: EIN Presswire

Introducing the first Aston Baker Cutting Edge Global Aesthetic Symposium Livestreamed from Colombia March 30-31, 2019.

NEW YORK CITY, NY, USA, February 28, 2019 /EINPresswire.com/ — Dr. Sherrell J. Aston and Dr. Daniel C. Baker are proud to announce the first Aston Baker Cutting Edge Global Aesthetic Symposium, "It's Just Surgery – Advanced Body Sculpting", which will premier this March 30 -31, 2019 from Bogota Colombia. The program has been designed for high impact learning by direct visualization of live surgery via live stream technology on the internet.

This symposium is based on the same high-level educational experience and state of the art plastic surgery innovation you have come to expect over the years from The Aston Baker Cutting Edge meeting in New York City.

High level curated content by Dr. Aston and Dr. Baker and a mix of U.S. and International surgeons operating live from four operating rooms will be simultaneously live streamed around the world, directly to your phone, tablet or computer.

Why Live Stream?

• Speed – Fastest and most efficient method of information transfer is through real-time observation of surgical operative cases. All that is necessary is a High-Speed internet connection.

• Methodology – A LIVE explanation of steps, techniques and surgical reasoning, allows for an immediate and accurate transfer of information in the latest state of the art medium that has become the second-best option after hands-on practice.

• Education – Earn CME credits in the comfort of your home, office or on the go while learning the latest advancements in Cutting Edge Body Contouring.

• Expense – Travel expenses associated with visiting physical locations for a meeting are now obsolete. In addition to a loss of revenue and time away from the office, live streaming surgery constitutes the most efficient transfer of information in the shortest amount of time.

Dr. Aston and Dr. Baker will be serving as Course Chairmen and moderating the symposium in the same format as they do for the New York City meeting every year.

Colombian Plastic Surgeon, Alfredo E. Hoyos, MD, will be acting as Program Director. Dr. Hoyos is the creator of High Definition Liposculpture and other advanced body contouring techniques, as well as author of "High Definition Body Sculpting: Art and Advanced Lipoplasty Techniques".

Surgeons Alfredo E. Hoyos, MD, Daniel A. Del Vecchio, MD, Constantino G. Mendieta, MD, Spero J. Theodorou, MD and Christopher T. Chia, MD will be performing live surgeries.

Dr. Daniel A. Del Vecchio is an internationally acclaimed plastic surgeon and inventor of the EVL (Expansion Vibration Lipofilling) technique for buttock shaping and lifting.

Dr. Constantino G. Mendieta has an international reputation as a world-renowned buttock enhancement expert and the author of "The Art of Gluteal Sculpting".

Dr. Spero J. Theodorou is an international figure within the field of plastic surgery, and a widely acclaimed expert on emerging technologies in body contouring and inventor of the non-excisional arm lift.

Dr. Christopher T. Chia is a recognized plastic surgeon from his excellent research and publications in body contouring as well as the inventor of the Brazilian Butt Lift Under Local Anesthesia (BUBBLA).

Doctors from all over the globe will have access to the best training and the brightest minds in cosmetic surgery. Experts will show their cutting-edge techniques and procedures for all to see.

This event will provide an exclusive and exceptional educational experience for surgeons who want to take their practice to another level with the fastest and most efficient method of information transfer through real-time observation of surgical operative cases.

For program details and registration visit our website at www.astonbakerglobal.com.

For press inquiries please contact:

Bernadette McGoldrick
Aston Baker Cutting Edge Global Aesthetic Symposium
+1 212-327-4681
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

DR. ASTON INTRODUCING THE FIRST EVER ASTON BAKER CUTTING EDGE GLOBAL AESTHETIC SYMPOSIUM – COLOMBIA


Source: EIN Presswire

National Survey Names Intermountain Healthcare as One of Nation’s Most Innovative Health Systems

New Intermountain Transformation Center

Healthcare leaders named Intermountain one of the top providers in the nation for innovation, high-quality care at sustainable costs, and thought leadership

SALT LAKE CITY, UTAH, USA, February 27, 2019 /EINPresswire.com/ — Healthcare leaders from across the country have named Intermountain Healthcare one of the top providers in the nation for innovation, high-quality care at a sustainable cost, and thought leadership.

A recent nationwide survey conducted by Reaction Data, a national healthcare research organization, asked 341 healthcare leaders to name the best health systems for innovation, quality care at sustainable costs, and thought leadership.

Intermountain Healthcare received the fourth-most mentions across all categories, following the Mayo Clinic, Cleveland Clinic, and Kaiser Permanente. Geisinger Health came in at number five. When the findings were adjusted to account for regional bias, Intermountain rose to number three overall.

Intermountain also received the fourth-most mentions for thought leadership and the third-most for quality of care and innovation.

“Intermountain Healthcare has a long-standing tradition of innovation guided by our mission to help people live the healthiest lives possible,” said Marc Harrison, MD, Intermountain president and CEO, and attributed the recognition to the ingenuity of Intermountain’s caregivers. “I’m honored to work with the best healthcare professionals who are taking bold and creative approaches to making care accessible for all people at the highest-possible quality and lowest-possible cost.”

Recent innovations at Intermountain that have gained national attention include the expansion of telehealth services such as Connect Care, a 24/7 online service that allows patients to receive care from Intermountain caregivers using interactive technology on their smartphones, tablets, and computers.

The Intermountain-led Civica Rx — a not-for-profit generic drug manufacturer and distributor — has also garnered praise for its innovative plans to make generic medications more available and affordable in hospitals across the nation. Also, changes in Intermountain’s supply chain have also saved tens of millions of dollars on medical supplies.

At the same time, Intermountain is committed to provide charitable care to people who can’t afford to pay for the services they need. Last year, the system provided more than $225.3 million worth of care for 236,446 patients — which averages more than $61,000 in free care provided every day to 647 patients.

The survey showed Intermountain's reputation for thought leadership is growing outside of the Intermountain West. For example, Intermountain received the fourth-most mentions for thought leadership, but only 11 percent of responses came from respondents in the western United States. By contrast, the Mayo Clinic received the most mentions for thought leadership, but 35 percent of responses came from health system leaders living inside their service areas.

To see the full results of the survey, click here https://www.reactiondata.com/wp-content/uploads/2019/02/Hospital-Brand-Equity-Reaction-Data-2019.pdf

Intermountain Healthcare is a Utah-based not-for-profit system of 23 hospitals, 170 clinics, a Medical Group with some 2,300 employed physicians and advanced care practitioners, a health insurance company called SelectHealth, and other health services. Intermountain is widely recognized as a leader in transforming healthcare through evidence-based best practices, high quality, and sustainable costs. For more information about Intermountain, visit intermountainhealthcare.org.

Daron Cowley
Intermountain Healthcare
801-442-2834
email us here


Source: EIN Presswire

CerSci Therapeutics Announces FDA Notification that First Clinical Trial of Non-Opioid Analgesic for Pain May Proceed

DALLAS, TEXAS, USA, February 27, 2019 /EINPresswire.com/ — CerSci Therapeutics, a non-opioid drug development firm based in Dallas, Texas, announced today that their Investigational New Drug (IND) application for CT-044 has received notification from the United States Food and Drug Administration (FDA) indicating that its Phase I safety and tolerability clinical trial may proceed. CT-044, a non-metal based, orally bioavailable, small molecule Radical Species Decomposition Accelerant (RSDAx) of peroxynitrite and hydrogen peroxide, is proposed for the treatment of acute and chronic pain, including acute post-surgical pain and painful diabetic neuropathy.

“Notification that our first study in the clinic may proceed marks a tremendous milestone for CerSci Therapeutics,” said Co-Founder and Chief Executive Officer Dr. Lucas Rodriguez. The transition of CT-044 from pre-clinical development into the clinic offers hope for patients needing an alternative to opiates in the treatment of pain. The need to address the opioid crisis is becoming ever more urgent; approximately 130 Americans die each day from an opioid overdose. We at CerSci believe that our new, non-opioid based therapy will be a more reliable and responsible treatment for pain, which will benefit both patients and caregivers.”

CerSci’s Chief Scientific Officer, Dr. Scott Dax added, “CT-044 operates by targeting and rapidly removing peroxynitrite in a catalytic manner.” Dr. Dax continued, “CT-044 disrupts or prevents ensuing cascades initiated by peroxynitrite that lead to neuronal hypersensitivity thereby providing a long duration of pain relief. The CT-044 platform offers tremendous potential for the design and development new drugs to completely change the way in which we treat pain and neurodegenerative diseases.”

Preclinical development work on CT-044 has been supported by a Phase II Small Business Innovation Research (SBIR Grant from the National Institutes of Health, titled “Orally Bioavailable Peroxynitrite Decomposition Catalyst Targeting Post Surgical Pain”).

About CerSci Therapeutics
With a focus on alleviating human suffering and rescuing society from the ongoing opioid crisis, CerSci Therapeutics is poised to deliver a new generation of non-opioid medicines to treat acute postoperative and chronic neuropathic pain (painful diabetic neuropathy).

Lucas Rodriguez
CerSci Therapeutics
+1 2149020484
email us here


Source: EIN Presswire